NVCR News and Press, NovoCure Limited From 10/29/20

Novocure Ltd (NVCR) Q3 2020 Earnings Conference Call October 29, 2020, 08:00 ET Company Participants Gabrielle Fernandes - Director, IR William Doyle - Executive Chairman Asaf Danziger - President, CEO & Director Ashley Cordova - CFO & VP, IR Ely Benaim - Chief Medical Officer Uri Wei...

The following slide deck was published by NovoCure Limited in conjunction with their 2020 Q3 earnings call. For further details see: NovoCure Limited 2020 Q3 - Results - Earnings Call Presentation

Novocure (NVCR) has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are elec...

NovoCure (NVCR): Q3 GAAP EPS of $0.09 beats by $0.05.Revenue of $132.66M (+44.1% Y/Y) beats by $12.64M.Gross margin of 79% compared to 75% for Q3 2019.Active patients at period end 3.36M, +22% Y/Y; Prescriptions received 1.37M, +4% Y/Y.Press Release For further details see: NovoCur...

Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020 Quarterly net income of $9.3 million with $0.09 in earnings per share Novocure (NASDAQ: NVCR) today reported fi...

Novocure (NASDAQ: NVCR) today announced it has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’...

NovoCure (NASDAQ:NVCR) is scheduled to announce Q3 earnings results on Wednesday, October 28th, after market close.The consensus EPS Estimate is $0.04 (+100.0% Y/Y) and the consensus Revenue Estimate is $120.02M (+30.3% Y/Y).Over the last 1 year, NVCR has beaten EPS estimates 25% of the time ...

Shares of NovoCure have doubled since July '20. The recent gains seem to have been inspired by the company teaming up with pharmaceutical giant, Merck, in first-line NSCLC, and growing acceptance in the medical community. Furthermore, many catalysts are on the horizon in 2021 and ...

As the pandemic resurges, early vaccine trials are reaching the home stretch. Vaccine results now pushed back to mid-to-late November at the earliest, and there have been delays in therapeutic treatments. Healthcare overall has been burdened by the uncertainty on the Affordable Ca...

Valuations for stocks such as Datadog (DDOG), DraftKings (DKNG), NovoCure (NVCR), and Chegg (CHGG) look stretched. The company's current and expected financials fail to justify their valuations. Its best to avoid these stocks for the remainder of this year. The S&P 500 has gained appr...